

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/806,038	03/22/2004	Sally Mackenzie	1231-218	1263
32905 ΙΟΝΟΙ Ε & Δ.	7590 05/01/200° SSOCIATES P.C.		EXAMINER	
858 HAPPY C	ANYON ROAD SUITE	E 230	KUBELIK, ANNE R	
CASTLE ROCK, CO 80108			ART UNIT	PAPER NUMBER
			1638	
			MAIL DATE	DELIVERY MODE
			05/01/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

· · · · · · · · · · · · · · · · · · ·		·			
	Application No.	Applicant(s)			
,	10/806,038	MACKENZIE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anne R. Kubelik	1638			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be timil apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status	•	•			
1) Responsive to communication(s) filed on 21 Fe	bruary 2007.				
2a) ☐ This action is FINAL . 2b) ☒ This	This action is FINAL . 2b)⊠ This action is non-final.				
• •	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 15 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>15</u> is/are rejected.					
7) Claim(s) is/are objected to.	·	0			
8) Claim(s) are subject to restriction and/or	election requirement.	•			
Application Papers					
9) The specification is objected to by the Examiner	•				
10) The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
11) I he oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form P1O-152.			
Priority under 35 U.S.C. § 119	, ·				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of	of the certified copies not receive	ed.			
Attachment(s)	_				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:				

Application/Control Number: 10/806,038 Page 2

Art Unit: 1638

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 21 February 2007 has been entered.

- 2. Claim 15 is pending.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. The rejection of claim 15 under 35 U.S.C. 102(b) as being anticipated by Rédei (1973, Mutation Res. 18:149-162) taken with the evidence of the instant specification is withdrawn in light of the Declaration of Sally Mackenzie.
- 5. The rejection of claim 15 under 35 U.S.C. 102(b) as being anticipated by Martínez-Zapater et al (1992, Plant Cell 4:889-899) taken with the evidence of the instant specification is withdrawn in light of the Declaration of Sally Mackenzie.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claim 15 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter that was not described in the

Application/Control Number: 10/806,038

Art Unit: 1638

specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claim is broadly drawn to any cytoplasmic male sterile plant made by suppressing the expression of an MSH1-homologous gene in the plant.

The instant specification, however, only provides guidance for identification of the MSH1 gene from Arabidopsis by gene mapping and cloning (example 1), comparison to potential CHM genes from other plant species (examples 2 and 4 and Figs 2-3); and transformation of Arabidopsis with the first 213 of the AtMSH1 gene (example 3). The only other guidance for reducing the expression of MSH1 in a plant is general (¶107-112). No cytoplasmic male sterile plant was made by suppressing the expression of an MSH1-homologous gene in a plant.

The instant specification fails to provide guidance for how to make a cytoplasmic male sterile plant made by suppressing the expression of an MSH1-homologous gene in the plant.

Sandhu et al (2007, Proc. Natl. Acad. Sci. USA 104:1766-1770) and the Declaration of Sally Mackenzie, filed 21 February 2007, state that mutation of the MSH1 gene in Arabidopsis does not create cytoplasmic male sterile plants (Sandhu et al, pg 1766, right column, paragraph 3; Declaration, pg 1). Thus, the only exemplified transformation would not produce the claimed cytoplasmic male sterile plants.

Further, Sandhu et al teach that suppression of Msh1 in tobacco and tomato required at least one crossing step (Table 1), which is not taught by the instant specification, and not present in the instant claims.

Application/Control Number: 10/806,038

Art Unit: 1638

Given the claim breath, unpredictability, and lack of guidance as discussed above, undue experimentation would have been required by one skilled in the art to develop and evaluate a cytoplasmic male sterile plant made by suppressing the expression of an MSH1-homologous gene in the plant.

8. Claim 15 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claim is broadly drawn to any cytoplasmic male sterile plant made by suppressing the expression of an MSH1-homologous gene in the plant.

The specification fails to describe the structure required for the recited function.

No species are described or reduced to practice in the specification.

Thus, one of skill in the art would not recognize that Applicant was in possession of the necessary common attributes or features of the genus.

Conclusion

- 9. No claim is allowed
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the

Art Unit: 1638

USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne Kubelik, Ph.D. April 24, 2007

ANNE KUBELIK, PH.D. PRIMARY EXAMINER